Kornimate/medical-research-clean huggingface dataset:
comparative effects of weight bearing and non-weight bearing exercises in patients with total hip replacement

Conditions: Total Hip Replacement

Summary: to compare the effects of weight bearing and non-weight bearing exercises on pain, range of motion and disability in patients with total hip replacement


Eligibility criteria:
inclusion criteria: * unilateral total hip arthroplasty * posterolateral approach of hip replacement * patients that were willing to participate * patients with 2 weeks post-operative history of total hip replacement exclusion criteria: * history of any systemic pathology * individual suffering from congenital hip disease. * bilateral total hip arthroplasty * evidence of cns involvement and any other neurological involvement * any red flag (malignancies or any kind of tumor * history of lower extremity fracture. * patient having any local or systemic infection of hip joint

Keywords: weight bearing exercise hip pain replacement arthroplasty range of motion
impact of atorvastatin versus rosuvastatin on 25 hydroxy vitamin d levels in patients with acute coronary syndrome

Conditions: Acute Coronary Syndromes

Summary: there will be 2 groups of patients with acute coronary syndrome. the patients will receive one of the 2 study drugs and impact on raising vitamin d level will be seen after 6 months

this randomized clinical trial will include 152 patients of acute coronary syndrome with normal vitamin d levels. they will be randomized to receive either atorvastatin or rosuvastatin. after 6 months of therapy, the impact on vitamin d levels will be checked

Eligibility criteria:
inclusion criteria: acute coronary syndrome 25 oh-vitamin d levels between 30-70ng/ml exclusion criteria: hypercalcemia hypocalcemia pregnancy lactation hypersensitivity to statins hypothyroidism deranged lfts \& rfts use of following within last 3 months (vitamin d supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)

Keywords: atorvastatin rosuvastatin vitamin d triglyceride lipid profile
serotonin receptor blockers in ischemic mitral regurgitation

Conditions: Ischemic Mitral Regurgitation

Summary: this study is intended to investigate the effect of cyproheptadine (a 5ht2b receptor blocker) on mitral regurgitation severity.

ischemic mitral regurgitation (mr) is a common and morbid complication of myocardial infarction (mi), doubling heart failure and mortality with currently limited therapies. its mechanisms have been previously linked to left ventricle (lv) remodeling with secondary deformation of otherwise normal mitral leaflets. recent studies are introducing new mechanistic elements, allowing possibilities for potential pharmacotherapeutic approaches. normal mitral leaflets have the capacity to enlarge and adapt to even the largest lv dilatation to prevent mr. however, this compensatory mechanism is insufficient after mi, and the leaflets are abnormally thick with fibrotic changes. those fibrotic changes could be related to a variation in blood serotonin (5-ht) levels after mi, which has been previously reported. serotonin is a known cause of valve fibrosis through its 5ht type 2b receptor. in sheep models, the investigators have tested the hypothesis that a 5ht type 2b receptor blocker (cyproheptadine) can prevent adverse remodeling in the valve after mi. cyproheptadine treatment was associated with increased valve leaflet surface, attenuated leaflet thickening and collagen deposition. importantly, treated animals had less mr compared to non-treated animals. thus the present study is a double-blind randomized trial to assess the effect of cyproheptadine on mr severity, mitral valve surface variation, and left ventricular size following mi. serial imaging (3d echo and mri) will assess valve adaptation, lv remodeling and mr.

Eligibility criteria:
inclusion criteria: 1. patients 18-80 years old with a 1st episode of stemi with documented coronary obstruction. 2. left ventricle ejection fraction (lvef)\<50% and mitral tenting area ≥ 4 cm2, or lvef ≤ 40% and inferior/posterior wall motion anomaly, or lvef≤30% and wall motion in any territory. exclusion criteria: 1. inability to provide informed consent 2. hemodynamic instability / cardiogenic shock / papillary muscle rupture 3. prior mitral valve procedure/surgery 4. permanent atrial fibrillation (limiting imaging and mr quantification) 5. primary mitral disease (endocarditis, rheumatic, degenerative or congenital) 6. more than mild valvular disease (other than mitral) at baseline 7. planned cardiac surgery (cabg or valve intervention) within 3 months 8. contraindications for mri 9. ongoing treatment with selective serotonin reuptake inhibitor (ssri) 10. chronic use of sedative medication 11. ongoing or planned pregnancy 12. chronic renal failure with estimated glomerular filtration rate (egfr) \< 30 ml/min 13. neurocognitive disorder 14. symptom or prior episode of urinary obstruction or glaucoma (relative contraindications for cyproheptadine)

Keywords: ischemic mitral regurgitation myocardial infarction mitral valve serotonin cyproheptadine
testicular function after testicular torsion

Conditions: Testicular Torsion; Spermatic Cord Torsion

Summary: the purpose of this study is to evaluate testicular function measured as testosterone level and semen quality.

men having undergone surgery for testicular torsion between 01.01.2003 - 12.31.2012 will receive a invitation to participate in this study. it is expected that 110 patients can be identified and about 65% of them will participate. these men will undergo a andrological evaluation, deliver a semen sample, have a blood sample taken and undergo a testicular ultrasound. control group: men attending the fertility counseling at herlev hospital will be offered participation in this study. the fertility counseling demands that men who contact the clinic have never had their sperm analyzed, have not tried to get pregnant with their partner for more than a year and that they have no prior knowledge of their fertility. primary endpoint: * semen quality measured as sperm concentration * total testosterone level secondary endpoint: semen parameters * semen volume (ml) * sperm concentration (x 106/ml) * sperm motility (%) (både klasse ab og abc) * sperm morphology * iga-bound spermatozoa (%) * igg-bound spermatozoa (%) hormones * fsh * lh * prl * testosterone * estradiol * inhibin b * insulin-like peptide 3 * shbg data points: * paternity * time to pregnancy * partner (yes/no) * any fertility treatment? * pain? (vas score) * symptoms of testesterone deficiency symptoms * andrological evaluation * testicular ultrasound * testicular torsion events in the family * date of surgery * date of follow up meeting * surgery details

Eligibility criteria:
inclusion criteria: * men with a verified testicular torsion operated at herlev and gentofte hospital between 01.01.2003 and 12.31.2012 exclusion criteria: * retentio testis * varicocele * previous treatment with chemo- or radiation therapy * genetic disposition for infertility * anejculation * retrograde ejaculation

Keywords: fertility testicular torsion testicular function
the clinical utility of measuring the circadian clock in treatment of delayed sleep-wake phase disorder

Conditions: Delayed Sleep Phase Syndrome

Summary: this study will test whether measuring the circadian clock during treatment of delayed sleep-wake phase disorder results in greater improvements in sleep compared to estimating the circadian clock.

the study is a randomized, controlled, parallel double-blind 4-week trial of 0.5 mgs of exogenous melatonin timed to either 3 h before actual dim light melatonin onset (dlmo) based on in-home measurement (m-dlmo, n = 25) or 3 h before dlmo estimated at 2 h before average sleep onset time based on actigraphy and sleep diary (e-dlmo, n = 25) in adult participants with delayed sleep-wake phase disorder. all participants will receive melatonin 0.5 mgs. outcomes include change in dlmo, subjective and objective sleep parameters, and daytime symptoms. as of january 7, 2020, the insomnia severity index was removed from the irb-approved protocol. no data were collected for this measure.

Eligibility criteria:
inclusion criteria: * meet diagnostic criteria for delayed sleep wake phase disorder * female participants of childbearing potential must agree to use a reliable method of contraception from the screening visit until 4 weeks after the study has completed. exclusion criteria: * hypersensitivity to melatonin or any other component of the product * sleep disorder other than delayed sleep wake phase disorder * medical and psychiatric conditions that may influence sleep or be affected by melatonin * current use of medications which may have interactions with melatonin * pregnancy or breastfeeding * routine night shift work * past month travel or planned travel during the study across more than one time zone * use of melatonin in the past month * current use of medications that may interfere with the measurement of melatonin
dynamic gait index in children with dyslexia

Conditions: Dyslexia; Gait Disorders, Neurologic

Summary: the aim of the present study is to investigate reliability in dyslexic children and compare it with healthy peers.

assessments methods are very important for the detection and treatment of such problems and there is a need for studies that can be applied for the dyslexia group. however fewer attempts have been made to demonstrate the reliability of balance impairments tools in dyslexic children. the dgi is a test that has been used a lot lately because of its minimal requirement for space and equipment, as well as its ability to be used with different patients' groups. the aim of the present study is to investigate reliability in dyslexic children and compare it with healthy peers.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of dyslexia by child and adolescent psychiatry * intelligence quotient (iq)\> 85 results of wisc-r * age between 8 - 14 * able to understand the commands given * volunteer to study exclusion criteria: * having cognitive disorder * having neuromuscular disorder * having skeletal anomaly * having visual or hearing problems

Keywords: dynamic gait index reliability balance gait
is the routine pressure dressing after thyroidectomy necessary?

Conditions: Thyroid Neoplasms; Thyroid Nodules; Graves Disease; Goiter

Summary: thyroidectomy is an operation that is commonly performed. after an operation a pressure dressing by hypafix is usually used due to the belief that it will help to reduce complications such as post-operative bleeding or haematoma. however, the practice is uncomfortable to patients and makes it hard to detect early haematomas. we carried out a prospective randomised study to study the role of pressure dressing after thyroid surgery by evaluating the amount of fluids collected in the operative bed by ultrasonography compared with normal dressing.

thyroidectomy is an operation that is commonly performed. in department of otolaryngology, khonkaen university was performed this operation about 200 cases per years. after an operation a pressure dressing by hypafix is usually used due to the belief that it will help to reduce complications such as post-operative bleeding or haematoma. however, the practice is uncomfortable to patients and makes it hard to detect early haematomas. we carried out a prospective randomised study to study the role of pressure dressing after thyroid surgery by evaluating the amount of fluids collected in the operative bed by ultrasonography compared with normal dressing.

Eligibility criteria:
inclusion criteria: * patients underwent thyroidectomy in srinagarind hospital, khonkaen university exclusion criteria: * patients with cervical lymph nodes metastases requiring neck dissection * patients that tissue pathology shown anaplastic carcinoma * patients with clinical or laboratory indicators of coagulation disorders

Keywords: thyroid thyroidectomy dressing
liver-enriched antimicrobial peptide 2

Conditions: Type 2 Diabetes

Summary: the investigators aim to investigate the physiological importance of leap-2 in healthy volunteers focusing on its potential insulinotropic effects.

the dramatic and almost immediate effects of roux-en-y gastric bypass (rygb) surgery on type 2 diabetes (t2d) can only in part be explained by alterations in the plasma concentrations of known peptides. thus, other - yet unknown - signals or hormones elicited from the endocrine cells of the small intestine may play an important role for the remission of t2d observed following rygb. in a recent study, a predicted sequence of liver-enriched antimicrobial peptide 2 (leap-2) was shown to induce a glucose-stimulated insulin secretion in isolated human pancreatic islets. the fragment was subsequently identified to be circulating in human plasma in concentrations comparable to the circulating levels of other known gut secreted hormones, hereby validating that leap-2 is an endogenous circulating peptide. the investigators hypothesise that leap-2 increases insulin secretion during a graded glucose infusion as assessed by plasma insulin and c-peptide compared with saline (placebo) in healthy subjects. the study is designed as a clinical, placebo-controlled, double-blinded cross-over study involving two experimental study days and ten young healthy male participants. the co-primary endpoints are the difference in plasma insulin levels during a graded glucose infusion and beta-cell secretion assessed by plasma c-peptide concentration relative to plasma glucose concentration between the two study days with either saline (placebo) or leap-2 infusion.

Eligibility criteria:
inclusion criteria: * caucasian men * age between 18 and 25 years * body mass index between 20-25 kg/m2 * informed consent exclusion criteria: * anaemia (haemoglobin below normal range) * alat and/or asat \>2 times normal values or history of hepatobiliary and/or gastrointestinal disorder(s) * nephropathy (serum creatinine above normal range and/or albuminuria) * any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses * any ongoing medication that the investigator evaluates would interfere with trial participation. * first- and second-degree relatives with diabetes * regular tobacco smoking
pharmacologic treatment in legal offenders with schizophrenia, a prospective observational mirror image study.

Conditions: Schizophrenia

Summary: considering the vulnerability of patients with schizophrenia in forensic treatment, we have designed a prospective-observational trial. the purpose of our study, notably its focus on selecting the appropriate medication, developing clinical profiles, and determining the grounds of clinical judgment, is relevant for treating patients with schizophrenia.

patients with a schizophrenia spectrum disorder who commit violent crimes appear to have some distinguishing characteristics. the current view is that crime committed in the course of a psychiatric illness, particularly schizophrenia, is treatable and preventable. nonetheless, treatment options for this patient group are sparse. the evidence regarding the efficacy and safety of such treatments is practically nonexistent. in practice therapeutic options are limited to medication and even here there is only one antipsychotic (clozapine) which has the current view is that crime committed during a psychiatric illness, particularly schizophrenia, is treatable and preventable. nonetheless, treatment options for this patient group are sparse. the evidence regarding the efficacy and safety of such treatments is practically nonexistent. in practice, therapeutic options are limited to medication; even here, almost no controlled clinical trials are investigating this issue. in clinical practice, selecting specific psychopharmacological treatments for patients with schizophrenia showing violent or aggressive behavior is particularly demanding. the lack of evidence regarding treatments for this particular group is partly attributable to their dual vulnerability and the consequent restrictions on clinical and experimental trials. paradoxically, the efforts to ensure the safety and rights of these patients put them at a disadvantage, as they have no access to evidence-based treatment for their condition. therefore, at best, they experience limited or slow improvement in their condition or, at worst, receive potentially ineffective or deleterious treatment. to address the lack of evidence regarding the efficacy and safety of antipsychotic treatment options for this particular population, the investigators have designed a prospective observational study with evaluation in a mirror image design. this reduces confounders at the level of a randomized controlled trial, allowing for robust statistical analysis.

Eligibility criteria:
inclusion criteria * participants are competent to give informed consent. * participants are between 18 and 65 years of age. * diagnosis of schizophrenia dsm-5 * violent crime in the course of a psychotic episode. * german language proficiency exclusion criteria * low intelligence * current neurological disorder * substance induced psychotic disorder

Keywords: schizophrenia pharmacologic treatment forensic treatment antipsychotics violent behavior
oral manifestations of coronavirus disease 2019(covid-19) :a multicentre study

Conditions: Covid19

Summary: online questionnaire will be distributed in different country to detect the oral change in patient diagnosed with covid-19

an online survey will be performed through google form. investigators in different country will share the questionnaire with patient diagnosed positive covid-19. data collected will be statically analyse to detect the oral picture of the virus.

Eligibility criteria:
inclusion criteria: * positive covid-19 exclusion criteria: * children * patient not confirmed by swab
fenofibrate and metformin insulin sensitivity in type 2 diabetics study

Conditions: Type 2 Diabetes; Dyslipidemia

Summary: double-blind, randomized placebo-controlled study in type 2 diabetes and dyslipidemic patients.patients will be randomized to one of four treatment arms for 16 weeks: placebo, fenofibrate, metformin, or metformin and fenofibrate combination.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes mellitus and dyslipidemia. exclusion criteria: * type 1 diabetes.

Keywords: type 2 diabetes dyslipidemia hyperinsulinemic clamp metformin fenofibrate
cognitive remediation of autobiographical memory in schizophrenia using sensecam®

Conditions: Schizophrenia Cognition Autobiographical Memory Cognitive Remediation

Summary: the aim of the study is to assess the efficiency of sensecam® in patients with schizophrenia by comparing two cognitive remediation methods of autobiographical memory.patients and control participants will be invited to carry sensecam® during 7 hours per day minimum and for 4 successive days. each ending day when carry sensecam®, they will be asked to go to the laboratory where 4 types of interventions will be successively done according to the randomization: 1) a simple visual retrospective procedure (svr), 2) a visual retrospective procedure coupled with a specific cueing intervention (vr-sc), 3) a verbal retrospective (vbr) and 4) no intervention (control condition).the testing phase will take place 14 days after the last day of data collection and will consist in a cued recall task and a recognition task using the pictures obtained by the sensecam® of the participants.according to our hypotheses, the vividness of memories will be higher in events subjected to the vr-sc procedure than in events subjected to the svr and vbr procedures. this effect is expected for both patients with schizophrenia and controls participants. since strategies to enrich memory details will be explicitly given to the patients when using the vr-sc procedure, we assume that patients will be able to normalize their scores.


Eligibility criteria:
inclusion criteria: * for both patients and controls * male or female willing to participate and who have signed up the legal document * under the protection of health insurancefor patients only * schizophrenia or schizo-affective disorder according to the dsm-iv * tr criteria * clinically stable for at least 2 monthsfor controls only * no psychiatric history exclusion criteria: * for both patients and controls * current severe or unstable somatic illness * neurological history (epilepsia, brain injury, brain surgery...) * current substance use disorder (dsm-iv-tr) * current major depressive disorder (dsm-iv-tr) * mental retardation (iq \< 70) * pregnancy, breast feeding * current legal controlfor patients only * treatment comprising benzodiazepines * benzodiazepines intake during the last 3 weeksfor controls only * psychotropic intake during the last 3 weeks
ketohexokinase isoforms in endometrial cancer.

Conditions: Endometrial Cancer

Summary: our preliminary analysis with clinical database suggested that, in patients with type i endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. to understand the importance of ketohexokinase expression and isoform switch during the development of type i endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.


Eligibility criteria:
inclusion criteria: * \>20 years * women with endometrial cancer who are about to be admitted to hospital for gynecological staging. * women who have undergone gynecological staging surgery for endometrial cancer in the past. exclusion criteria: * women with endometrial cancer who receive preoperative chemotherapy or radiation therapy.